0000899243-19-028978.txt : 20191211
0000899243-19-028978.hdr.sgml : 20191211
20191211194047
ACCESSION NUMBER: 0000899243-19-028978
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191210
FILED AS OF DATE: 20191211
DATE AS OF CHANGE: 20191211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANIA EDWIN M JR
CENTRAL INDEX KEY: 0001255927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 191280794
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-10
0
0001682852
Moderna, Inc.
MRNA
0001255927
KANIA EDWIN M JR
C/O FLAGSHIP PIONEERING, INC.
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
2019-12-10
4
S
0
100000
18.8084
D
498847
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.75 to $18.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
1. Edwin M. Kania, Jr. is filing this report as a 10% stockholder as a result of his relationship with the Flagship Entities (defined below), which collectively hold more than 10% of the shares of the Issuer.
2. This report relates solely to the personal transactions in the shares of the Issuer by Edwin M. Kania, Jr. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), which is the general partner of each of Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. (the "Flagship IV Funds" and, together with Flagship Fund IV GP and Flagship Pioneering, Inc., the "Flagship Entities"). While Mr. Kania is retired from Pioneering, he continues to serve as a manager of Flagship Fund IV GP. The Flagship Entities together with Dr. Afeyan and Mr. Kania, file separate Section 16 reports disclosing the extent of Mr. Kania's Section 16 beneficial ownership in transactions by the Flagship Entities.
Edwin M. Kania, Jr. By: /s/ Edwin M. Kania, Jr.
2019-12-11